BenevolentAI S.A. (BAI.AS)
EUR 0.4
(-4.31%)
EUR 0.4
(-4.31%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.82 Million GBP | -32.79% |
| 2022 | 5.68 Million GBP | -21.01% |
| 2021 | 7.2 Million GBP | -14.58% |
| 2020 | 8.43 Million GBP | -16.24% |
| 2019 | 10.06 Million GBP | 0.0% |
| 2018 | - GBP | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 3.82 Million GBP | -24.89% |
| 2023 Q2 | 5.09 Million GBP | -10.51% |
| 2023 FY | 3.82 Million GBP | -32.79% |
| 2022 Q4 | 5.68 Million GBP | -10.89% |
| 2022 Q2 | 6.38 Million GBP | -11.36% |
| 2022 FY | 5.68 Million GBP | -21.01% |
| 2021 Q4 | 7.2 Million GBP | 0.0% |
| 2021 FY | 7.2 Million GBP | -14.58% |
| 2020 FY | 8.43 Million GBP | -16.24% |
| 2019 FY | 10.06 Million GBP | 0.0% |
| 2018 FY | - GBP | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -247.23% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 91.447% |
| Adocia SA | 4.54 Million EUR | 15.793% |
| Aelis Farma SA | 2.04 Million EUR | -86.67% |
| Biophytis S.A. | 3.11 Million EUR | -22.887% |
| Advicenne S.A. | 15.89 Million EUR | 75.95% |
| genOway Société anonyme | 5.51 Million EUR | 30.734% |
| IntegraGen SA | 642.28 Thousand EUR | -495.223% |
| Medesis Pharma S.A. | 1.2 Million EUR | -218.583% |
| Neovacs S.A. | 650 Thousand EUR | -488.154% |
| NFL Biosciences SA | 39.2 Thousand EUR | -9651.805% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 12.246% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -95.018% |
| Sensorion SA | 1.24 Million EUR | -208.08% |
| Theranexus Société Anonyme | 2.46 Million EUR | -55.361% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 1.924% |
| TheraVet SA | 1 Million EUR | -282.071% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 44.642% |
| argenx SE | 15.35 Million EUR | 75.101% |
| BioSenic S.A. | 15.57 Million EUR | 75.451% |
| Celyad Oncology SA | 902 Thousand EUR | -323.836% |
| DBV Technologies S.A. | 4.52 Million USD | 15.532% |
| Galapagos NV | 4.94 Million EUR | 22.674% |
| Genfit S.A. | 62.25 Million EUR | 93.859% |
| GeNeuro SA | 6.49 Million EUR | 41.115% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1011.337% |
| Innate Pharma S.A. | 30.6 Million EUR | 87.509% |
| Inventiva S.A. | 25.61 Million EUR | 85.076% |
| MaaT Pharma SA | 5.42 Million EUR | 29.53% |
| MedinCell S.A. | 52.8 Million EUR | 92.759% |
| Nanobiotix S.A. | 41.66 Million EUR | 90.823% |
| Onward Medical N.V. | 16.3 Million EUR | 76.555% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -10.792% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 89.233% |
| Oxurion NV | 117 Thousand EUR | -3167.521% |
| Pharming Group N.V. | 123.65 Million EUR | 96.908% |
| Poxel S.A. | 40.14 Million EUR | 90.477% |
| GenSight Biologics S.A. | 1.04 Million EUR | -264.79% |
| Transgene SA | 17 Thousand EUR | -22388.235% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.867% |
| Valneva SE | 132.76 Million EUR | 97.121% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |